This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (50)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Herbert L. DuPont, MD; Charles D. Ericsson, MD; John J. Mathewson, PhD; F. J. de la Cabada, MD; Dennis A. Conrad, MD

JAMA. 1992;267(14):1932-1935.

Abstract
Objective.
—To evaluate a poorly absorbed antimicrobial with in vitro activity against all major bacterial enteropathogens in oral therapy for bacterial diarrhea.

Design.
—One hundred ninety-one US students with diarrhea acquired in Mexico received 100 mg of aztreonam or matching placebo three times a day for 5 days. Stools were cultured for bacterial enteropathogens before and after therapy.

Setting.
—We studied US students who acquired diarrhea in Mexico (travelers' diarrhea) in view of the high frequency of bacterial agents in this setting.

Main Outcome Measure.
—We examined time of clinical recovery, treatment failures, adverse experiences, and microbiologic eradication from stool of the etiologic agent in subjects randomized to receive aztreonam or placebo.

Results.
—Aztreonam reduced the average duration of diarrhea compared with the placebo: for all cases, by 40 hours (P<<.01); for those with enterotoxigenic Escherichia coli diarrhea, by 50 hours (P<.01); for those with shigellosis, by 90 hours (P, not significant [small sample size]); for all bacterial agents, by 57 hours (P<<.01). Clinical failures during the 5 days of therapy were seen in six patients (6%) receiving aztreonam and 25 (27%) receiving placebo (P<.01). Pathogen eradication occurred in 95% of those receiving aztreonam and in 70% of those receiving the placebo (P<.01). All bacterial enteropathogens were susceptible in vitro to aztreonam. The drug was well tolerated.

Conclusions.
—Oral aztreonam, which is poorly absorbed, was well tolerated and was an effective therapy for bacterial diarrhea in US adults in Mexico.

(JAMA. 1992;267:1932-1935)

Author Affiliations
From the Center for Infectious Diseases, University of Texas Medical School/School of Public Health, Houston, Tex (Drs DuPont, Ericsson, and Mathewson); Hospital General de Occidente, Guadalajara, Jalisco, Mexico (Dr de la Cabada); and Bristol-Myers Squibb, Princeton, NJ (Dr Conrad).

Footnotes
Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ill, September 30, 1991.

Reprint requests to 6431 Fannin, Room 1.729 JFB, Houston, TX 77030 (Dr DuPont).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Global Etiology of Travelers' Diarrhea: Systematic Review from 1973 to the Present
Shah et al.
Am J Trop Med Hyg 2009;80:609-614.
ABSTRACT | FULL TEXT  

Noroviruses as a Cause of Traveler's Diarrhea among Students from the United States Visiting Mexico
Ko et al.
J. Clin. Microbiol. 2005;43:6126-6129.
ABSTRACT | FULL TEXT  

Enterotoxigenic Escherichia coli in Developing Countries: Epidemiology, Microbiology, Clinical Features, Treatment, and Prevention
Qadri et al.
Clin. Microbiol. Rev. 2005;18:465-483.
ABSTRACT | FULL TEXT  

Enteric Pathogens in Mexican Sauces of Popular Restaurants in Guadalajara, Mexico, and Houston, Texas
Adachi et al.
ANN INTERN MED 2002;136:884-887.
ABSTRACT | FULL TEXT  

Prevention and Treatment of Traveler's Diarrhea
DuPont and Ericsson
NEJM 1993;328:1821-1827.
FULL TEXT  

AZTREONAM FOR TRAVELERS' DIARRHEA
JWatch General 1992;1992:5-5.
FULL TEXT